EIGR(Delisted)
Eiger·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EIGR
Eiger Biopharmaceuticals, Inc.
A commercial-stage biopharmaceutical company that develops innovative therapies for hepatitis delta virus (HDV) and other serious diseases
2155 Park Boulevard, Palo Alto, CA 94306
--
Eiger BioPharmaceuticals, Inc., was formed by the merger of Celladon Corporation and BioPharmaceuticals, Inc., on March 22, 2016. BioPharmaceuticals, Inc., incorporated in California, USA on December 21, 2000 and re-merged in Delaware in April 2012, is a commercial-stage biopharmaceutical company focused on developing innovative therapies for delta virus (HDV) and other serious diseases. In their portfolio, all of their rare disease programs are designated as breakthrough therapies by the U.S. Food and Drug Administration.
Company Financials
EPS
EIGR has released its 2023 Q3 earnings. EPS was reported at -0.41, versus the expected -0.32, missing expectations. The chart below visualizes how EIGR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EIGR has released its 2023 Q4 earnings report, with revenue of 3.80M, reflecting a YoY change of 41.06%, and net profit of -13.45M, showing a YoY change of 46.48%. The Sankey diagram below clearly presents EIGR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
